236 related articles for article (PubMed ID: 21850019)
1. Immunomodulation by imiquimod in patients with high-risk primary melanoma.
Narayan R; Nguyen H; Bentow JJ; Moy L; Lee DK; Greger S; Haskell J; Vanchinathan V; Chang PL; Tsui S; Konishi T; Comin-Anduix B; Dauphine C; Vargas HI; Economou JS; Ribas A; Bruhn KW; Craft N
J Invest Dermatol; 2012 Jan; 132(1):163-9. PubMed ID: 21850019
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
3. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
Papakostas D; Stockfleth E
Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707
[TBL] [Abstract][Full Text] [Related]
4. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
Adams S; Kozhaya L; Martiniuk F; Meng TC; Chiriboga L; Liebes L; Hochman T; Shuman N; Axelrod D; Speyer J; Novik Y; Tiersten A; Goldberg JD; Formenti SC; Bhardwaj N; Unutmaz D; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6748-57. PubMed ID: 22767669
[TBL] [Abstract][Full Text] [Related]
5. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
6. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
Ellis LZ; Cohen JL; High W; Stewart L
Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
8. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
Fleming CJ; Bryden AM; Evans A; Dawe RS; Ibbotson SH
Br J Dermatol; 2004 Aug; 151(2):485-8. PubMed ID: 15327559
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
Akkilic-Materna M; Massone C; Komericki P
Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
[TBL] [Abstract][Full Text] [Related]
12. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
[TBL] [Abstract][Full Text] [Related]
13. Clearance of invasive melanoma with topical imiquimod.
Moon SD; Spencer JM
J Drugs Dermatol; 2013 Jan; 12(1):107-8. PubMed ID: 23377337
[TBL] [Abstract][Full Text] [Related]
14. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
Wagstaff AJ; Perry CM
Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
[TBL] [Abstract][Full Text] [Related]
15. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
17. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
18. Periocular Melanoma In Situ Treated With Imiquimod.
Elia MD; Lally SE; Hanlon AM; Choi JN; Servat JJ; Shields JA; Shields CL; Levin F
Ophthalmic Plast Reconstr Surg; 2016; 32(5):371-3. PubMed ID: 26325381
[TBL] [Abstract][Full Text] [Related]
19. Topical Imiquimod for Management of Recurrent Lentigo Maligna Melanoma in Situ.
Bartenjev MS; Isaković-Vidović S; Bartenjev I
Acta Dermatovenerol Croat; 2020 Jul; 28(1):34-37. PubMed ID: 32650849
[TBL] [Abstract][Full Text] [Related]
20. Using topical imiquimod for the management of positive in situ margins after melanoma resection.
Pandit AS; Geiger EJ; Ariyan S; Narayan D; Choi JN
Cancer Med; 2015 Apr; 4(4):507-12. PubMed ID: 25620351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]